BIRC5
Baculoviral IAP repeat-containing protein 5
Also known as: API4, BIRC5_HUMAN, EPR-1, survivin
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O15392
- Gene
- BIRC5
- Ensembl
- ENSG00000089685
- Chromosome
- 17
- Canonical length
- 142 aa
- Protein class
- Cancer-related genes, Predicted intracellular proteins
- Subcellular location
- Cytokinetic bridge
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene is a member of the inhibitor of apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. IAP family members usually contain multiple baculovirus IAP repeat (BIR) domains, but this gene encodes proteins with only a single BIR domain. The encoded proteins also lack a C-terminus RING finger domain. Gene expression is high during fetal development and in most tumors, yet low in adult tissues. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jun 2011]
Canonical amino-acid sequenceUniProt
142 residues, UniProt reviewed canonical sequence.
>O15392|BIRC5
1 MGAPTLPPAW QPFLKDHRIS TFKNWPFLEG CACTPERMAE AGFIHCPTEN EPDLAQCFFC
61 FKELEGWEPD DDPIEEHKKH SSGCAFLSVK KQFEELTLGE FLKLDRERAK NKIAKETNNK
121 KKEFEETAKK VRRAIEQLAA MDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BIRC5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 38 nTPM
Expression across tissuesHPA
Tissue
- thymus: 38 nTPM
- bone marrow: 36 nTPM
- testis: 19 nTPM
- tonsil: 15 nTPM
- lymph node: 15 nTPM
- esophagus: 13 nTPM
Single-cell type
- late primary spermatocytes: 284 nCPM
- extravillous trophoblasts: 178 nCPM
- esophageal basal cells: 169 nCPM
- erythrocyte progenitors: 155 nCPM
- migrating cytotrophoblasts: 141 nCPM
- monocyte progenitors: 135 nCPM
Immune cell
- T-reg: 14 nTPM
- memory CD4 T-cell: 4.1 nTPM
- total PBMC: 3.1 nTPM
- memory CD8 T-cell: 2.8 nTPM
- memory B-cell: 2.4 nTPM
- NK-cell: 2.4 nTPM
Brain region
- thalamus: 2 nTPM
- white matter: 1.4 nTPM
- cerebral cortex: 1.1 nTPM
- medulla oblongata: 1.1 nTPM
- pons: 1.1 nTPM
- basal ganglia: 0.9 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about BIRC5.
Disease | ImmuneIEDB
Conditions an epitope on BIRC5 was assayed in.
- melanoma T cell
- intrahepatic cholangiocarcinoma T cell
- glioblastoma B and T cell
- prostate adenocarcinoma B cell
- chronic lymphocytic leukemia T cell
- prostate cancer T cell
- colon adenocarcinoma T cell
- neuroendocrine tumor T cell
- childhood hepatocellular carcinoma T cell
- renal cell carcinoma T cell
- pancreatic adenocarcinoma T cell
- colorectal cancer T cell
- skin melanoma T cell
- ovary epithelial cancer T cell
- leukemia T cell
- head and neck cancer T cell
- breast cancer T cell
- adenoid cystic carcinoma T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against BIRC5 are reported. Each links to that disease's full target list.
Showing 1 of 2 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for BIRC5 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
24 publications
- Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients.
2000 · Cancer Res · RCR 3.1 · 148 citations - Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis.
2005 · Arthritis Res Ther · RCR 1.9 · 81 citations - Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
2005 · Lung Cancer · RCR 1.4 · 68 citations - Detection of autoantibodies to survivin and livin in sera from patients with breast cancer.
2005 · Clin Chim Acta · RCR 1.2 · 62 citations - Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
2017 · Tumour Biol · RCR 1 · 29 citations
Show 19 more
- Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma.
2024 · PeerJ · RCR 0.9 · 4 citations - Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients.
2004 · Clin Chem · RCR 0.7 · 27 citations - Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer.
2010 · Clin Chem Lab Med · RCR 0.6 · 22 citations - Plasma anti-BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer.
2018 · FEBS Open Bio · RCR 0.6 · 15 citations - Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma.
2005 · Autoimmunity · RCR 0.4 · 14 citations - A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer.
2016 · Tumour Biol · RCR 0.4 · 9 citations - Diagnostic Value of the Survivin Autoantibody in Four Types of Malignancies.
2018 · Genet Test Mol Biomarkers · RCR 0.4 · 8 citations - Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors.
2007 · Int J Oncol · RCR 0.4 · 16 citations - Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer.
2015 · FEBS Open Bio · RCR 0.3 · 11 citations - Autoantibody against survivin in patients with systemic sclerosis.
2010 · J Rheumatol · RCR 0.3 · 10 citations - Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma.
2015 · Mol Clin Oncol · RCR 0.2 · 6 citations - Survivin promoter polymorphisms and autoantibodies in endometriosis.
2012 · J Reprod Immunol · RCR 0.2 · 5 citations - Detection of autoantibodies against survivin in sera from cancer dogs.
2010 · J Vet Med Sci · RCR 0.2 · 7 citations - Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status.
2016 · Cancer Immunol Res · RCR 0.2 · 5 citations - Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer.
2012 · Asian Pac J Cancer Prev · RCR 0.2 · 7 citations - [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].
2010 · Zhongguo Fei Ai Za Zhi · RCR 0.2 · 8 citations - Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer.
2015 · FEBS Open Bio · RCR 0.1 · 6 citations - Detection of autoantibodies to survivin in cervical mucus from patients with human papillomavirus-associated cervical cancer and precursor lesions.
2007 · Autoimmunity · RCR 0.1 · 3 citations - Autoantibodies to survivin in the sera of patients with infiltrating ductal carcinoma of the breast.
2006 · Med J Malaysia · RCR 0 · 2 citations
Reference: B cellIEDB
2 publications
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.
2016 · Cancer Immunol Immunother · RCR 4.6 · 146 citations - Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.
2013 · J Immunother · RCR 0.2 · 8 citations
Reference: T cellIEDB
17 publications
- Actively personalized vaccination trial for newly diagnosed glioblastoma.
2019 · Nature · RCR 26.4 · 742 citations - Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
2022 · Nat Biotechnol · RCR 4.9 · 84 citations - HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
2015 · Proc Natl Acad Sci U S A · RCR 3.6 · 140 citations - Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
2017 · J Hematol Oncol · RCR 3.4 · 120 citations - Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
2014 · Cancer Immunol Immunother · RCR 2.9 · 91 citations
Show 12 more
- Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study.
2022 · Clin Cancer Res · RCR 1.7 · 29 citations - Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
2012 · Cancer Immunol Immunother · RCR 1.7 · 68 citations - Full-length dominant-negative survivin for cancer immunotherapy.
2003 · Clin Cancer Res · RCR 1.5 · 80 citations - High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes.
2018 · Front Oncol · RCR 1 · 28 citations - Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.
2016 · Case Rep Med · RCR 0.7 · 25 citations - Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
2020 · Elife · RCR 0.6 · 17 citations - NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
2018 · Cancer Immunol Immunother · RCR 0.5 · 13 citations - Preclinical development of HIvax: Human survivin highly immunogenic vaccines.
2015 · Hum Vaccin Immunother · RCR 0.5 · 13 citations - Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
2016 · J Immunother Cancer · RCR 0.3 · 10 citations - Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
2022 · Front Immunol · RCR 0.2 · 3 citations - Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.
2025 · Front Immunol · 1 citations - Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case.
2025 · J Immunother Cancer
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.04
- gnomAD pLI
- 0.06
- gnomAD missense Z
- 0.47
- DepMap mean gene effect
- -1.81
- DepMap dependency class
- pan
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- cell division
- chromosome localization
- chromosome segregation
- G2/M transition of mitotic cell cycle
- mitotic cell cycle
- mitotic cytokinesis
- mitotic spindle assembly
- mitotic spindle assembly checkpoint signaling
- mitotic spindle midzone assembly
- mitotic spindle organization
- negative regulation of apoptotic process
- negative regulation of DNA-templated transcription
- positive regulation of attachment of mitotic spindle microtubules to kinetochore
- positive regulation of cell population proliferation
- positive regulation of exit from mitosis
- positive regulation of mitotic cell cycle
- positive regulation of mitotic cell cycle spindle assembly checkpoint
- positive regulation of mitotic cytokinesis
- positive regulation of mitotic sister chromatid separation
- protein-containing complex localization
- sensory perception of sound
Molecular functions
- cobalt ion binding
- cysteine-type endopeptidase inhibitor activity
- cysteine-type endopeptidase inhibitor activity involved in apoptotic process
- enzyme binding
- identical protein binding
- metal ion binding
- microtubule binding
- protein heterodimerization activity
- protein homodimerization activity
- protein-folding chaperone binding
- small GTPase binding
- tubulin binding
- zinc ion binding
Cellular components
- centriole
- chromosome passenger complex
- chromosome, centromeric region
- cytoplasm
- cytoplasmic microtubule
- cytosol
- interphase microtubule organizing center
- kinetochore
- microtubule
- microtubule cytoskeleton
- midbody
- nuclear chromosome
- nucleoplasm
- nucleus
- protein-containing complex
- spindle microtubule
- spindle midzone
- survivin complex
Protein domainsUniProt · Pfam · InterPro
- BIR repeat
- Inhibitor of Apoptosis domain
- Baculoviral IAP repeat-containing
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of BIRC5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BIRC5 as an antibody target. Whether an autoantibody or antibody against BIRC5 could matter depends on whether native BIRC5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BIRC5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label BIRC5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...